Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$30.07 USD
+0.76 (2.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $30.25 +0.18 (0.60%) 6:20 PM ET
5-Strong Sell of 5 5
D Value D Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Supernus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 1.32 | 60.71 | 53.42 | 126.95 | 113.06 |
Depreciation/Amortization & Depletion | 85.27 | 90.89 | 50.51 | 31.83 | 18.03 |
Net Change from Assets/Liabilities | -9.14 | -24.24 | 3.57 | -36.52 | 0.61 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 33.64 | -10.53 | 19.62 | 16.13 | 11.43 |
Net Cash From Operating Activities | 111.09 | 116.83 | 127.13 | 138.40 | 143.13 |
Property & Equipment | -0.55 | -0.41 | -2.05 | -3.45 | -2.74 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -311.69 | -298.54 | 0.00 |
Investments | 269.28 | -216.25 | 231.82 | 267.53 | -156.54 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -0.24 | 1.35 |
Net Cash from Investing Activities | 268.73 | -216.66 | -81.91 | -34.70 | -157.92 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 6.61 | 12.42 | 7.10 | 4.36 | 3.93 |
Issuance (Repayment) of Debt | -402.50 | 0.00 | -137.52 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -1.99 | -22.90 | 0.00 | -0.80 | 0.00 |
Net Cash from Financing Activities | -397.88 | -10.48 | -130.42 | 3.56 | 3.93 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -18.07 | -110.31 | -85.21 | 107.26 | -10.87 |
Cash at Beginning of Period | 93.12 | 203.43 | 288.64 | 181.38 | 192.25 |
Cash at End of Period | 75.05 | 93.12 | 203.43 | 288.64 | 181.38 |
Diluted Net EPS | 0.02 | 1.04 | 0.98 | 2.36 | 2.10 |
Fiscal Year End for Supernus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 1.32 | 0.14 | 16.12 | 16.95 |
Depreciation/Amortization & Depletion | NA | 85.27 | 62.87 | 40.94 | 20.08 |
Net Change from Assets/Liabilities | NA | -9.14 | -11.11 | -40.78 | 5.42 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 33.64 | 14.23 | 13.98 | 6.68 |
Net Cash From Operating Activities | NA | 111.09 | 66.13 | 30.25 | 49.13 |
Property & Equipment | NA | -0.55 | -0.59 | -0.44 | -0.28 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 269.28 | 335.30 | 300.51 | 240.06 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 268.73 | 334.71 | 300.08 | 239.78 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 6.61 | 3.53 | 3.76 | 1.81 |
Issuance (Repayment) of Debt | NA | -402.50 | -402.50 | -402.50 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 78.36 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -1.99 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | -397.88 | -398.97 | -398.74 | 80.17 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -18.07 | 1.87 | -68.41 | 369.08 |
Cash at Beginning of Period | NA | 93.12 | 93.12 | 93.12 | 93.12 |
Cash at End of Period | NA | 75.05 | 94.99 | 24.71 | 462.20 |
Diluted Net EPS | NA | 0.04 | -0.29 | -0.02 | 0.29 |